INTERVENTION 1:	Intervention	0
Celecoxib	Intervention	1
celecoxib	CHEBI:41423	0-9
Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.	Intervention	2
celecoxib	CHEBI:41423	43-52
hormone	CHEBI:24621	78-85
receptor	BAO:0000281	86-94
Celecoxib: Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.	Intervention	3
celecoxib	CHEBI:41423	0-9
celecoxib	CHEBI:41423	42-51
disease	DOID:4,OGMS:0000031	86-93
INTERVENTION 2:	Intervention	4
Placebo	Intervention	5
Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.	Intervention	6
hormone	CHEBI:24621	68-75
receptor	BAO:0000281	76-84
Placebo: Two capsules once daily with food	Intervention	7
food	CHEBI:33290	38-42
Inclusion Criteria:	Eligibility	0
Completely resected (greater or equal 1mm), histologically or cytologically proven unilateral breast cancer	Eligibility	1
unilateral	HP:0012833	83-93
breast cancer	DOID:1612	94-107
Female greater or equal 18 years of age	Eligibility	2
female	PATO:0000383	0-6
age	PATO:0000011	36-39
If (neo) adjuvant chemotherapy received, patient must have received at least 4 cycles. Chemotherapy must be completed prior to study entry	Eligibility	3
adjuvant	CHEBI:60809	9-17
patient	HADO:0000008,OAE:0001817	41-48
Hormone Receptor negatives must have received prior chemotherapy	Eligibility	4
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
Study entry must be within any of the following timelines: 3 months of the end of definitive breast surgery OR between 3 weeks and 4 months after day 1 of the last cycle of adjuvant chemotherapy OR 6 weeks of the end of radiotherapy.	Eligibility	5
breast	UBERON:0000310	93-99
surgery	OAE:0000067	100-107
day	UO:0000033	146-149
adjuvant	CHEBI:60809	173-181
radiotherapy	OAE:0000235	220-232
WHO performance status 0 or 1	Eligibility	6
Pre-treatment haematology and biochemistry values within acceptable local limits: Haemoglobin, white blood cell greater or equal to 3.0 x 109/l or absolute neutrophil count greater or equal to 1.51 x 109/l, Platelets greater or equal to 100 x 109/l, Serum bilirubin less than 1.5 x upper normal limit , Alkaline phosphatase less or equal to 1.5 x upper normal limit , Serum creatinine less than 1.5 x upper normal limit	Eligibility	7
blood	UBERON:0000178	101-106
x	LABO:0000148	136-137
x	LABO:0000148	198-199
x	LABO:0000148	241-242
x	LABO:0000148	280-281
x	LABO:0000148	345-346
x	LABO:0000148	399-400
phosphatase	GO:0016791,BAO:0000295	312-323
creatinine	CHEBI:16737	374-384
Negative pregnancy test for patients with child-bearing potential	Eligibility	8
Normal baseline ECG and clinical cardiovascular assessment after completion of all (neo) adjuvant chemotherapy	Eligibility	9
adjuvant	CHEBI:60809	89-97
No previous or current evidence for metastatic disease	Eligibility	10
disease	DOID:4,OGMS:0000031	47-54
Be accessible for and consent to long term follow-up	Eligibility	11
Written informed consent prior to commencement of specific protocol procedures must be obtained and documented according to the local regulatory requirements	Eligibility	12
Exclusion Criteria	Eligibility	13
Patients with node negative, T1, Grade 1 breast cancer	Eligibility	14
breast cancer	DOID:1612	41-54
Unresectable, metastatic or bilateral breast cancer	Eligibility	15
bilateral breast cancer	DOID:6741	28-51
Active or previous peptic ulceration or gastrointestinal bleeding in the last year	Eligibility	16
active	PATO:0002354	0-6
year	UO:0000036	78-82
Active or previous history of inflammatory bowel disease	Eligibility	17
active	PATO:0002354	0-6
history	BFO:0000182	19-26
inflammatory bowel disease	DOID:0050589	30-56
A past history of adverse reaction/hypersensitivity to NSAIDs, including celecoxib and salicylates, or sulphonamides	Eligibility	18
history	BFO:0000182	7-14
celecoxib	CHEBI:41423	73-82
salicylates	CHEBI:26596	87-98
On current or planned chronic NSAIDs therapy (except low dose aspirin 100 mg four times per day or 325mg once daily).	Eligibility	19
chronic	HP:0011010	22-29
day	UO:0000033	92-95
Current or long-term use of oral corticosteroids	Eligibility	20
Known or suspected congestive heart failure (greater than New York Heart Association I) and/or coronary heart disease, previous history of myocardial infarction, uncontrolled arterial hypertension (ie BP greater than 160/90mmHg) under treatment with two anti-hypertensive drugs, rhythm abnormalities requiring permanent treatment.	Eligibility	21
congestive heart failure	HP:0001635,DOID:6000	19-43
heart	UBERON:0000948	30-35
heart	UBERON:0000948	67-72
heart	UBERON:0000948	104-109
heart disease	DOID:114	104-117
history	BFO:0000182	128-135
myocardial infarction	HP:0001658,DOID:5844	139-160
hypertension	HP:0000822,DOID:10763	184-196
Patients with diabetes controlled by diet and oral medication are eligible for the study however patients with insulin dependent diabetes are excluded	Eligibility	22
insulin	CHEBI:145810	111-118
excluded	HP:0040285	142-150
Past history of stroke/Transient ischaemic attack, symptomatic peripheral vascular disease or carotid disease	Eligibility	23
history	BFO:0000182	5-12
peripheral vascular disease	DOID:341	63-90
disease	DOID:4,OGMS:0000031	83-90
disease	DOID:4,OGMS:0000031	102-109
Previously entered into an adjuvant chemotherapy trial for which approval for entry into REACT has not been granted	Eligibility	24
adjuvant	CHEBI:60809	27-35
ER receptor status unknown, Human epidermal growth factor receptor 2 or FISH positive, or Human epidermal growth factor receptor 2 status unknown	Eligibility	25
receptor	BAO:0000281	3-11
receptor	BAO:0000281	58-66
receptor	BAO:0000281	120-128
growth factor	BAO:0002024	44-57
growth factor	BAO:0002024	106-119
14. Hormone Receptor negative and not received (neo)adjuvant chemotherapy 15. Use of hormone replacement therapy within the last 6 weeks 16. Pregnant or lactating women or women of childbearing potential unwilling/unable to use non-hormonal contraception 17. No previous or concomitant malignancies except adequately treated squamous cell / basal cell carcinoma of the skin, in situ carcinoma of the cervix or ductal carcinoma in situ/lobular carcinoma in situ of the breast, unless there has been a disease-free interval of 10 years or more 18. Psychiatric or addictive disorders which could preclude obtaining informed consent 19. Clinical evidence of severe osteoporosis and/or history of osteoporotic fracture	Eligibility	26
hormone	CHEBI:24621	4-11
hormone	CHEBI:24621	85-92
receptor	BAO:0000281	12-20
adjuvant	CHEBI:60809	52-60
basal cell carcinoma	HP:0002671,DOID:2513	341-361
in situ carcinoma	DOID:8719	375-392
carcinoma	HP:0030731,DOID:305	352-361
carcinoma	HP:0030731,DOID:305	383-392
carcinoma	HP:0030731,DOID:305	417-426
carcinoma	HP:0030731,DOID:305	443-452
breast	UBERON:0000310	468-474
severe	HP:0012828	654-660
osteoporosis	HP:0000939,DOID:11476	661-673
history	BFO:0000182	681-688
Outcome Measurement:	Results	0
Disease Free Survival (DFS) Benefit of Two Years Adjuvant Therapy With the COX-2 Inhibitor Celecoxib Compared With Placebo in Primary Breast Cancer Patients.	Results	1
disease	DOID:4,OGMS:0000031	0-7
adjuvant	CHEBI:60809	49-57
inhibitor	CHEBI:35222	81-90
celecoxib	CHEBI:41423	91-100
breast cancer	DOID:1612	134-147
From time of randomisation to the date of first event; with events contributing to the analysis defined as loco-regional and distant breast cancer recurrence, new primary breast cancer (ipsilateral or contralateral) and death without disease relapse (intercurrent death)	Results	2
time	PATO:0000165	5-9
breast cancer	DOID:1612	133-146
breast cancer	DOID:1612	171-184
death	OAE:0000632	220-225
death	OAE:0000632	264-269
disease	DOID:4,OGMS:0000031	234-241
Time frame: Patients will be followed up to 10 years. DFS will be calculated from date of randomization until the date of first documented DFS event, this will be assessed at 2 and 5 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Celecoxib	Results	5
celecoxib	CHEBI:41423	17-26
Arm/Group Description: Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.	Results	6
celecoxib	CHEBI:41423	66-75
hormone	CHEBI:24621	101-108
receptor	BAO:0000281	109-117
Celecoxib: Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.	Results	7
celecoxib	CHEBI:41423	0-9
celecoxib	CHEBI:41423	42-51
disease	DOID:4,OGMS:0000031	86-93
Overall Number of Participants Analyzed: 1763	Results	8
Measure Type: Number	Results	9
Unit of Measure: Percentage of participants  2 Year DFS rate: 91        (90 to 93)	Results	10
year	UO:0000036	47-51
rate	BAO:0080019	56-60
5 Year DFS rate: 84        (82 to 86)	Results	11
year	UO:0000036	2-6
rate	BAO:0080019	11-15
Results 2:	Results	12
Arm/Group Title: Placebo	Results	13
Arm/Group Description: Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.	Results	14
hormone	CHEBI:24621	91-98
receptor	BAO:0000281	99-107
Placebo: Two capsules once daily with food	Results	15
food	CHEBI:33290	38-42
Overall Number of Participants Analyzed: 876	Results	16
Measure Type: Number	Results	17
Unit of Measure: Percentage of participants  2 Year DFS rate: 90        (87 to 92)	Results	18
year	UO:0000036	47-51
rate	BAO:0080019	56-60
5 Year DFS rate: 83        (81 to 86)	Results	19
year	UO:0000036	2-6
rate	BAO:0080019	11-15
Adverse Events 1:	Adverse Events	0
Total: 148/1755 (8.43%)	Adverse Events	1
Anaemia * 1/1755 (0.06%)	Adverse Events	2
Neutropenia * 0/1755 (0.00%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	0-11
Thrombocytopenia * 0/1755 (0.00%)	Adverse Events	4
thrombocytopenia	HP:0001873,DOID:1588	0-16
Thrombocytopenic purpura * 1/1755 (0.06%)	Adverse Events	5
purpura	HP:0000979,DOID:3326	17-24
Acute cardiac event * 1/1755 (0.06%)	Adverse Events	6
acute	HP:0011009,PATO:0000389	0-5
Aortic valve incompetence * 1/1755 (0.06%)	Adverse Events	7
valve	UBERON:0003978	7-12
Arrhythmia * 1/1755 (0.06%)	Adverse Events	8
arrhythmia	HP:0011675	0-10
Atrial fibrillation * 1/1755 (0.06%)	Adverse Events	9
atrial fibrillation	HP:0005110,DOID:0060224	0-19
Cardiac failure * 0/1755 (0.00%)	Adverse Events	10
Cardiac tamponade * 0/1755 (0.00%)	Adverse Events	11
cardiac tamponade	HP:0033415,DOID:115	0-17
Adverse Events 2:	Adverse Events	12
Total: 64/868 (7.37%)	Adverse Events	13
Anaemia * 2/868 (0.23%)	Adverse Events	14
Neutropenia * 2/868 (0.23%)	Adverse Events	15
neutropenia	HP:0001875,DOID:1227	0-11
Thrombocytopenia * 1/868 (0.12%)	Adverse Events	16
thrombocytopenia	HP:0001873,DOID:1588	0-16
Thrombocytopenic purpura * 0/868 (0.00%)	Adverse Events	17
purpura	HP:0000979,DOID:3326	17-24
Acute cardiac event * 0/868 (0.00%)	Adverse Events	18
acute	HP:0011009,PATO:0000389	0-5
Aortic valve incompetence * 0/868 (0.00%)	Adverse Events	19
valve	UBERON:0003978	7-12
Arrhythmia * 1/868 (0.12%)	Adverse Events	20
arrhythmia	HP:0011675	0-10
Atrial fibrillation * 0/868 (0.00%)	Adverse Events	21
atrial fibrillation	HP:0005110,DOID:0060224	0-19
Cardiac failure * 1/868 (0.12%)	Adverse Events	22
Cardiac tamponade * 1/868 (0.12%)	Adverse Events	23
cardiac tamponade	HP:0033415,DOID:115	0-17
